In ₹ Crore except Per Share Latest Annual | AARTIPHARM FY26 | AARTIDRUGS FY26 | ADVENZYMES FY26 | AGARWALEYE FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 43.02× | 20.46× | ◆ 20.04× | 118.81× | 20.46× +110% | |
| P/B | 3.54× | 2.57× | ◆ 2.01× | 7.48× | 2.57× +37% | |
| EV/EBITDA | 22.19× | 14.74× | ◆ 11.83× | 27.67× | 14.74× +51% | |
| Market Cap | ₹7,516 Cr | ₹3,988 Cr | ₹3,382 Cr | ₹15,846 Cr | ₹3,988 Cr +88% | |
| Growth | ||||||
| Revenue CAGR 3Y | -2.20% | -1.89% | ◆ 11.32% | — | 4.71% -147% | |
| Revenue CAGR 5Y | — | 3.55% | ◆ 8.24% | — | 5.89% | |
| Net Income CAGR 3Y | -3.35% | 5.43% | ◆ 18.68% | — | 12.05% -128% | |
| Revenue YoY (latest Q) | ◆ 38.74% | 19.01% | 2.08% | 25.97% | 19.01% +104% | |
| Net Income YoY (latest Q) | ◆ 53.82% | -7.12% | -4.58% | 44.56% | -4.58% +1275% | |
| Profitability | ||||||
| EBITDA Margin | 20.29% | 12.05% | ◆ 30.72% | 27.38% | 27.38% -26% | |
| Net Income Margin | 9.60% | 7.60% | ◆ 23.28% | 8.08% | 8.08% +19% | |
| Return on Common Equity | 8.13% | ◆ 12.58% | 10.02% | 6.28% | 10.02% -19% | |
| Return on Capital Employed | 10.41% | ◆ 12.80% | 10.91% | 8.43% | 10.91% -5% | |
| Return on Assets | 5.02% | 6.92% | ◆ 9.44% | 4.27% | 6.92% -27% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.32× | 0.37× | ◆ 0.01× | 0.07× | 0.07× +357% | |
| Interest Coverage | 5.65× | 7.19× | ◆ 71.91× | 3.24× | 7.19× -21% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹1,819 Cr | ₹2,565 Cr | ₹746 Cr | ₹2,080 Cr | ₹2,080 Cr -13% | |
| Net Income | ₹175 Cr | ₹195 Cr | ₹174 Cr | ₹168 Cr | ₹174 Cr +1% | |
| Total Assets | ₹3,482 Cr | ₹2,815 Cr | ₹1,839 Cr | ₹3,942 Cr | ₹2,815 Cr +24% | |
| EPS | ₹19.27 | ₹21.36 | ₹15.08 | ₹4.21 | ₹15.08 +28% | |
| Book Value per Share | ₹234.35 | ₹169.74 | ₹150.38 | ₹66.91 | ₹150.38 +56% | |